On December 2, China’s securities regulator published that Surgerii Robotics (SHURUI) has officially filed for A-share IPO counseling with CITIC Securities. This marks the company’s second IPO attempt within two years.

Surgerii originally entered the IPO preparation phase in 2023, during a period when several Chinese surgical robotics companies were exploring listings. As market sentiment cooled rapidly, many initiatives—including Surgerii’s—paused. Two years later, with technology maturing, regulatory pathways stabilizing, and hospital procurement logic shifting, Surgerii is restarting its listing process. Unlike the previous cycle-driven momentum, this attempt appears to be a deliberate internal decision based on the company’s current stage of development, signaling growing maturity in the single-port robotic space.

Financing and Governance

Between 2019 and 2023, Surgerii completed six rounds of financing. Shunwei Capital led investments from Series A through later rounds—an unusually consistent investment trajectory in China’s medical device sector, reflecting strong long-term confidence in Surgerii’s technology roadmap.

On the strategic side, Medtronic China Fund joined from the B+ round and continued investing in Series C. The fact that a global surgical robotics leader invested in a Chinese single-port platform suggests that Surgerii’s technological direction has international comparability and engineering feasibility.

According to IPO counseling documents, founder Dr. Kai Xu controls approximately 54.58% of voting rights, enabling stable and long-term alignment in R&D strategy.

Rather than rushing to list after completing counseling in 2023, the company spent the following two years strengthening indication expansion, system stability, clinical feedback loops, and supply chain robustness. The renewed IPO process appears to reflect Surgerii’s internal conclusion that “the timing is now right.”

From Columbia University Research to a Chinese Single-Port Robotics Platform

Surgerii’s technological trajectory is closely tied to the research background of its founder.

Dr. Kai Xu earned his PhD from Columbia University, working under robotic surgery pioneer Russell Taylor. During his doctoral studies, he contributed to some of the world’s earliest single-port robotic prototypes, at a time when Intuitive Surgical dominated the global market with high prices and slow iteration cycles. This environment crystallized his ambition to build the next generation of surgical robots.

After returning to China, Dr. Xu established a research program on continuum mechanisms and snake-like instruments at Shanghai Jiao Tong University. This work later became the foundation of Surgerii’s system: the “dual continuum deformable mechanism.” Its ability to operate with high degrees of freedom in extremely narrow spaces addresses one of the central engineering challenges of single-port surgery.

Founded in 2014, Surgerii chose to focus exclusively on single-port robotics, building a full technology stack—from continuum structures and snake arms to master–slave control and 3D endoscopic imaging—rather than relying on supply-chain integration.This bottom-up R&D approach enabled Surgerii to develop a fully independent knowledge system over a decade, supporting its progress in expanding indications and achieving engineering maturity.

December 4, 2025, MedChina